{"log_id": 1182569208504080494, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 2e-06, "average": 0.998805, "min": 0.994783}, "location": {"width": 546, "top": 237, "height": 29, "left": 218}, "words": "是,即使是波谷浓度的达托霉素也有可能引起相互作用"}, {"probability": {"variance": 0.00067, "average": 0.993285, "min": 0.843943}, "location": {"width": 743, "top": 282, "height": 28, "left": 264}, "words": "对于正接受本品治疗的患者,如果出现异常高的PT/INR结果,建议医生采取"}, {"probability": {"variance": 0, "average": 0.999709, "min": 0.999126}, "location": {"width": 92, "top": 326, "height": 27, "left": 220}, "words": "以下措施"}, {"probability": {"variance": 0.025381, "average": 0.931489, "min": 0.376259}, "location": {"width": 711, "top": 371, "height": 28, "left": 296}, "words": "要求恰好在下一次本品给药前(即在波谷浓度时)采样。重复PT/NR的"}, {"probability": {"variance": 0.003594, "average": 0.978717, "min": 0.726741}, "location": {"width": 787, "top": 414, "height": 29, "left": 218}, "words": "评价。如果在波谷浓度时采样的PT/INR值仍然离于预期的值,则应考虑使用其它"}, {"probability": {"variance": 0.003775, "average": 0.97815, "min": 0.767373}, "location": {"width": 227, "top": 458, "height": 27, "left": 218}, "words": "方法对PT/INR进行评价"}, {"probability": {"variance": 0.000587, "average": 0.988282, "min": 0.904424}, "location": {"width": 500, "top": 504, "height": 28, "left": 295}, "words": "对其它原因引起的异常升高的PT/INR结果进行评价"}, {"probability": {"variance": 0.012515, "average": 0.919325, "min": 0.717932}, "location": {"width": 127, "top": 554, "height": 28, "left": 222}, "words": "〖药物过量〗"}, {"probability": {"variance": 1.2e-05, "average": 0.998273, "min": 0.98612}, "location": {"width": 739, "top": 592, "height": 28, "left": 263}, "words": "药物过量时,建议进行支持治疗以维持肾小球滤过作用。通过血液透析(4"}, {"probability": {"variance": 2.9e-05, "average": 0.997671, "min": 0.968594}, "location": {"width": 786, "top": 636, "height": 29, "left": 219}, "words": "小时以上可消除相当于所给剂量约15%的药物)或腹膜透析(48小时以上可消除"}, {"probability": {"variance": 0.005252, "average": 0.985088, "min": 0.551592}, "location": {"width": 790, "top": 680, "height": 28, "left": 216}, "words": "相当于所给剂量约11%的药物),达托霉素能从体内缓慢清除。在进行血液透析的"}, {"probability": {"variance": 6e-05, "average": 0.99746, "min": 0.957551}, "location": {"width": 651, "top": 724, "height": 28, "left": 215}, "words": "4小时内使用高通量透析膜比使用低通量膜可以增加清除的药物量"}, {"probability": {"variance": 0.02617, "average": 0.920443, "min": 0.559328}, "location": {"width": 125, "top": 777, "height": 27, "left": 223}, "words": "【药理毒理〗"}, {"probability": {"variance": 0, "average": 0.999166, "min": 0.998285}, "location": {"width": 96, "top": 814, "height": 28, "left": 261}, "words": "药理作用"}, {"probability": {"variance": 0.042847, "average": 0.910193, "min": 0.403277}, "location": {"width": 136, "top": 859, "height": 27, "left": 276}, "words": "()微生物学"}, {"probability": {"variance": 7.2e-05, "average": 0.99552, "min": 0.96032}, "location": {"width": 747, "top": 902, "height": 32, "left": 260}, "words": "达托霉素属于环脂肽类抗生素,在临床上用于治疗因需氧革兰阳性菌导致的"}, {"probability": {"variance": 0.000313, "average": 0.994851, "min": 0.901544}, "location": {"width": 708, "top": 947, "height": 29, "left": 215}, "words": "感染。达托霉素的体外抗菌谱覆盖大多数与临床有关的革兰阳性病原菌"}, {"probability": {"variance": 0.000132, "average": 0.996341, "min": 0.933983}, "location": {"width": 802, "top": 977, "height": 48, "left": 260}, "words": "达托霉素在体外对革兰阳性菌显示出快速、浓度依赖性的杀菌活性。采用肉"}, {"probability": {"variance": 0.003615, "average": 0.973991, "min": 0.748538}, "location": {"width": 826, "top": 1036, "height": 33, "left": 213}, "words": "汤稀释法得出的时间-杀菌曲线和最小杀菌浓度/最小抑菌浓度 MBCMIC)比值"}, {"probability": {"variance": 0.00176, "average": 0.987866, "min": 0.770734}, "location": {"width": 790, "top": 1081, "height": 30, "left": 213}, "words": "已经证实达托霉素的上述活性。在模拟的心内膜赘生物中,达托霉素对稳定期金"}, {"probability": {"variance": 9e-06, "average": 0.998451, "min": 0.985397}, "location": {"width": 641, "top": 1125, "height": 31, "left": 213}, "words": "黄色葡萄球菌仍保持其体外杀菌活性。尚不知该结果的临床意义"}, {"probability": {"variance": 0.001927, "average": 0.989936, "min": 0.742598}, "location": {"width": 746, "top": 1169, "height": 31, "left": 260}, "words": "作用机制:达托霉素的作用机制不同于任何其他的抗生素。达托霉素与细菌"}, {"probability": {"variance": 6e-06, "average": 0.998525, "min": 0.987348}, "location": {"width": 790, "top": 1213, "height": 32, "left": 213}, "words": "细胞膜结合,并引起细胞膜电位的快速去极化。细胞膜电位的这种缺失抑制"}, {"probability": {"variance": 6e-06, "average": 0.99838, "min": 0.991347}, "location": {"width": 533, "top": 1260, "height": 28, "left": 213}, "words": "DNA、RNA和蛋白质的合成,最终导致细菌细胞死亡"}, {"probability": {"variance": 3.6e-05, "average": 0.996922, "min": 0.974368}, "location": {"width": 747, "top": 1303, "height": 32, "left": 258}, "words": "耐药机制:达托霉素耐药机制尚不完全清楚。目前,尚无已知的可转移成分"}, {"probability": {"variance": 6e-06, "average": 0.998588, "min": 0.991156}, "location": {"width": 255, "top": 1349, "height": 29, "left": 213}, "words": "能导致达托霉素的耐药性"}, {"probability": {"variance": 0.012922, "average": 0.94502, "min": 0.591036}, "location": {"width": 746, "top": 1394, "height": 29, "left": 259}, "words": "复杂性皮肤及软组织感染( CSSSI)试验:在一组Ⅱ期和关键性ⅢI期 CSSSI"}, {"probability": {"variance": 3.4e-05, "average": 0.99703, "min": 0.971395}, "location": {"width": 793, "top": 1439, "height": 29, "left": 213}, "words": "临床试验中,在两名细菌感染的患者中发现了达托霉素不敏感菌株。一个不敏感"}, {"probability": {"variance": 0.007393, "average": 0.982767, "min": 0.489474}, "location": {"width": 792, "top": 1482, "height": 33, "left": 213}, "words": "菌株是从一名进行Ⅱ期临床试验的患者体内分离出的金黄色葡萄球菌,该患者"}, {"probability": {"variance": 1.1e-05, "average": 0.998611, "min": 0.979949}, "location": {"width": 795, "top": 1527, "height": 30, "left": 212}, "words": "在最初的5天治疗时,使用的本品剂量低于方案规定的剂量。另一个不敏感菌株"}], "language": 3}